Biofrontera Inc - BFRI Operating Profitability

Official company branding of Biofrontera Inc. (BFRI)

Strict medical protocols ensure Biofrontera Inc. (BFRI) sustained demand and high margins for consumables. The actual operating margin demonstrates the efficiency of the core business, with the parameter reaching -0.60. Company revenues are based on the sale of approved dermatological products, which guarantees moderate predictability of cash flows. High physician confidence in the Ameluz system confirms the brand's impeccable reputation.

Biofrontera Inc. (BFRI): Return on Sales by Operating Profit from 07/04/2022 to 11/19/2026

Metric breakdowns and analytics for Biofrontera Inc (BFRI)

- price and consensus price forecast:
Fundamental company valuation:biofrontera-us.com, BFRI
Finished products of Biofrontera, Inc.

Operating margin measures cost management efficiency, determining the portion of revenue that remains as operating profit after covering all business operational expenses. The current operating income as a percentage of revenue stands at -0.60, reflecting the ability of Biofrontera Inc. (BFRI) to maintain profitability amidst intense pricing pressure and high marketing costs within the aggressive dermatology sector.